The impairment of the Growth Hormone/Insulin-like growth factor 1 (IGF-1) axis in heart failure: A possible target for future therapy

Lucrezia Piccioli, Michele Arcopinto, Andrea Salzano, Roberta D’Assante, Alessandra Schiavo, Francesca M. Stagnaro, Anna Lombardi, Veronica Panicara, Pietro Valente, Giuseppe Vitale, Filippo M. Sarullo, Francesco Giallauria, Alberto M. Marra

Research output: Contribution to journalArticlepeer-review

Abstract

Hormonal abnormalities are quite common in chronic heart failure (CHF). The most studied hormonal axis in CHF is the impairment of Growth Hormone (GH)/Insulin Growth Factor-1(IGF-1), which in turn is defined either by a blunted response to GH stimulation test or low serum IGF-1 values. Several independent groups reported that the presence of an abnormal GH/IGF-1 status in CHF is associated with a more severe disease, impaired functional capacity and reduced Survival rates. After the first encouraging results, double -blind controlled trials showed a neutral effect of the GH administration in patients. However, further studies reported positive results, when a GH-therapy is implemented only in those patients presenting a GH deficiency (replacement therapy).

Original languageEnglish
Pages (from-to)20-25
Number of pages6
JournalMonaldi Archives for Chest Disease
Volume88
Issue number3
DOIs
Publication statusPublished - Jan 1 2018

Keywords

  • Anabolic deficiency
  • Biomarker
  • Chronic heart failure
  • Growth hormone
  • IGF-1
  • Outcomes

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint

Dive into the research topics of 'The impairment of the Growth Hormone/Insulin-like growth factor 1 (IGF-1) axis in heart failure: A possible target for future therapy'. Together they form a unique fingerprint.

Cite this